Assenagon Asset Management S.A. Has $1.17 Million Stock Position in Humana Inc. $HUM

Assenagon Asset Management S.A. lowered its stake in Humana Inc. (NYSE:HUM) by 62.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,758 shares of the insurance provider’s stock after selling 11,454 shares during the period. Assenagon Asset Management S.A.’s holdings in Humana were worth $1,172,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Montag A & Associates Inc. lifted its holdings in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares during the period. CoreCap Advisors LLC raised its position in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac acquired a new position in Humana during the fourth quarter valued at approximately $27,000. Reflection Asset Management bought a new stake in Humana during the fourth quarter worth $29,000. Finally, Rosenberg Matthew Hamilton boosted its stake in Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $409.92 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. The company’s 50-day moving average is $314.71 and its 200-day moving average is $248.64. The stock has a market capitalization of $49.22 billion, a PE ratio of 43.84, a price-to-earnings-growth ratio of 2.26 and a beta of 0.71. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $414.82.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The business had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm’s revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the company posted $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. Equities research analysts expect that Humana Inc. will post 9.04 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s dividend payout ratio (DPR) is 37.86%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Piper Sandler restated a “neutral” rating and issued a $254.00 target price (up from $182.00) on shares of Humana in a research report on Wednesday, May 13th. Seaport Research Partners downgraded shares of Humana to a “neutral” rating in a research note on Wednesday, May 20th. Bank of America lifted their price target on shares of Humana from $340.00 to $380.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. Sanford C. Bernstein reissued an “outperform” rating and issued a $425.00 price objective on shares of Humana in a research note on Wednesday, June 3rd. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Humana in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus price target of $293.09.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.